[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7

Di |2024-10-19T00:30:01+02:00Ottobre 19th, 2024|Categorie: Coronavirus Lancet|

Oda Y, Kumagai Y, Kanai M, et al. 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7—In thi...

[Corrections] Correction to Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7

Di |2024-10-19T00:30:01+02:00Ottobre 19th, 2024|Categorie: Coronavirus Lancet|

Oda Y, Kumagai Y, Kanai M, et al. 12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine. Lancet Infect Dis 2024; published online Oct 7. https://doi.org/10.1016/S1473-3099(24)00615-7—In thi...

[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 27. https://doi.org.10.1016/S1473-3099(24)00618-2

Di |2024-10-19T00:30:01+02:00Ottobre 19th, 2024|Categorie: Coronavirus Lancet|

Brickley EB, Miranda-Filho DdB, Ximenes RAdA, on behalf of the MERG, ZBC-Consortium, and LIFE Zika Study members. Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zi...

[Corrections] Correction to Lancet Infect Dis 2024; published online Sept 27. https://doi.org.10.1016/S1473-3099(24)00618-2

Di |2024-10-19T00:30:01+02:00Ottobre 19th, 2024|Categorie: Coronavirus Lancet|

Brickley EB, Miranda-Filho DdB, Ximenes RAdA, on behalf of the MERG, ZBC-Consortium, and LIFE Zika Study members. Preparing for the rapid research response to the possible vertical transmission of Oropouche virus: lessons from a decade of congenital Zi...

[Comment] Molecular surveillance in the nirsevimab era: lessons from respiratory syncytial virus breakthrough infections

Di |2024-10-15T00:30:05+02:00Ottobre 15th, 2024|Categorie: Coronavirus Lancet|

Nirsevimab, a long-acting monoclonal antibody targeting site Ø of the fusion (F) protein of the respiratory syncytial virus (RSV), was approved by the European Medicines Agency and the US Food and Drug Administration for the prevention of RSV infection...

Torna in cima